Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6871 to 6885 of 8215 results

  1. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

    Technology appraisal guidance
    Discontinued

  3. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued Reference number: GID-TA10927

    Technology appraisal guidance
    Discontinued

  4. Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]

    Discontinued Reference number: GID-TA10934

    Technology appraisal guidance
    Discontinued

  5. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development Reference number: GID-TA10935 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued Reference number: GID-TA10963

    Technology appraisal guidance
    Discontinued

  7. Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma

    Discontinued Reference number: GID-TA10970

    Technology appraisal guidance
    Discontinued

  8. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development Reference number: GID-TA11010 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development Reference number: GID-TA11070 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Terevalefim for treating delayed graft function after kidney transplant [ID1490]

    Discontinued Reference number: GID-TA11098

    Technology appraisal guidance
    Discontinued

  12. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  13. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued Reference number: GID-TA11120

    Technology appraisal guidance
    Discontinued

  14. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

    Technology appraisal guidance
    Discontinued

  15. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development Reference number: GID-TA11157 Expected publication date: TBC

    Technology appraisal guidance
    In development